Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.1.1.8 (cholinesterase)
 12,691 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Oral toxicity, distribution and metabolism of a new multi-insect repellant, N,N-diethylphenylacetamide (DEPA) was studied in rats. On administration of DEPA (851 mg/kg body wt.) labelled with 14C blood, liver, stomach and stomach contents had 2.65, 3.97, 12.07 and greater than 50.66% radioactivity, respectively, after 20 min. Gas chromatographic analysis showed presence of both DEPA and its metabolite N-ethylphenylacetamide (EPA) in blood, liver, kidneys and lungs while only DEPA was present in stomach and stomach contents. EPA, phenylacetamide and conjugated phenylacetic acid were excreted along with unmetabolized parent compound in urine of rats when a low oral dose of DEPA (70 mg/kg body wt.) was administered. Activities of erythrocyte cholinesterase and carbonic anhydrase did not change significantly upon acute oral exposure to DEPA.
 ...
PMID:Distribution and metabolism of insect repellant N,N-diethylphenylacetamide on oral exposure in rats. 200 66

Cutaneous LD50 of N,N-diethylphenylacetamide (DEPA), a new multi insect repellent was 2200, 3200 and 7100 mg/kg body weight in female mice, rats and guinea pigs; and 1600 and 4000 mg/kg in male mice and rats indicating a high degree of safety on skin contact. Dermal application of DEPA to young growing rats for 21 days at a dose of 50 mg/kg did not exert any adverse effects while massive doses of 500 and 1000 mg/kg caused marked reduction of body weight gain and lowering of activities of serum alanine aminotransferase, aspartate aminotransferase and cholinesterase. Along with DEPA, N-ethylphenylacetamide, phenylacetamide and phenylacetic acid were detected in the urine of DEPA treated mice, rats and guinea pigs.
 ...
PMID:Toxicity and metabolism of a new insect repellent N,N-diethylphenylacetamide in mice, rats and guinea pigs on cutaneous application. 281 93

Administration of the irreversible cholinesterase inhibitor isoflurophate (diisopropylfluorophosphate, DFP) before 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) enhanced the loss in tyrosine hydroxylase activity and dopamine and 3,4-dihydroxy-phenylacetic acid content in the striatum of mice in a dose-dependent manner. The effect of DFP on the MPTP-induced changes of dopaminergic markers was evident 30 days after initiating treatment, suggesting augmented neurotoxicity. Neurotoxicity was also enhanced by prior treatment with nicotine, carbachol or oxotremorine. We conclude that activation of either muscarinic or nicotinic receptors enhances the neurotoxicity of MPTP.
 ...
PMID:Enhanced MPTP neurotoxicity after treatment with isoflurophate or cholinergic agonists. 791 17